An RNA:DNA “sandwich” plays a key role in behavioral adaptations arising from emotional experiences

Embargoed: Not for Release Until 2:00 pm U.S. Eastern Time Thursday, 12 December 2024.

A team of neuroscience researchers at the Medical University of South Carolina reports in Science the discovery of a new genetic regulatory mechanism involved in behavioral adaptations to emotional experiences in a preclinical model. Although such adaptations are crucial for survival, they can become problematic in patients with certain psychiatric disorders. Understanding the genetic changes that lead to maladaptive behaviors may help scientists to develop better RNA therapies to treat brain disorders.

The research team included Makoto Taniguchi, Ph.D., assistant professor in the Department of Neuroscience, Christopher Cowan, Ph.D., professor and chair of the Department of Neuroscience, and Rose Marie Akiki, an M.D.-Ph.D. student at MUSC. With funding from the National Institutes of Health and a pilot grant from the South Carolina Clinical & Translational Research Institute, the researchers set out to understand how clinically relevant emotional experiences, including chronic stress and drug use, lead to long-lasting changes in behavior. Ultimately, their findings show that loss of this genetic regulatory mechanism leads to reduced drug seeking and increased resilience to stress in mice.

“By understanding this process, we hope to get better insights into how changes in the brain can lead to maladaptive changes in behavior,” said Cowan. “We could also improve our fundamental understanding of how the brain works and how emotions and emotionally relevant experiences help to shape brain circuits.”

Scientists have long known that what we experience can cause changes in our brain, thereby altering how we behave. But how exactly do those changes occur? Well, it begins with our genes.

All cells within an individual contain essentially the same genes, but different genes can be turned on at different times. This variability allows our bodies to adapt to a changing environment. Importantly, well over half of the human genome is devoted to producing a specific type of regulatory molecules that help to control when and where critical protein-coding genes are turned on. These regulatory molecules, known as long non-coding RNAs (lncRNAs), have been found to differ in people with depression and substance use disorders.

The MUSC researchers focused on long non-coding enhancer RNA (Inc-eRNA), a specific type of lncRNA that interacts with the regulatory region of target genes. Upon binding to specific genes, Inc-eRNA can form unique structures, known as R-loops, to help to govern those genes.

The MUSC team looked at a gene called NPAS4, which is implicated in both stress-induced anhedonia, or lack of joy in activities that were once pleasurable, and drug-induced relapse. Their study provides the first evidence for the role of R-loops in governing behavioral changes induced by emotional experiences.

R-loops can help to turn on specific genes by forming an RNA:DNA “sandwich” in regulatory regions of a target gene. In the case of the NPAS4 gene, R-loops appear to help to bring the enhancer region, which includes instructions for turning on a gene and is located at a distance, together with the main body of the gene, including the important gene promoter region, and this allows the gene to be turned on in response to an experience.

“By bringing the enhancer and promoter together in space and time, R-loops seem to be facilitating their interaction and driving the response to turn on a gene,” said Cowan.

In response to emotional experiences, some people struggle more than others, and this may result in the development of maladaptive behaviors. For example, the death of a loved one is a very difficult experience to process that could lead some individuals to develop depression, while others are able to make peace with their loss. The specific behaviors the researchers analyzed in mice were cocaine seeking and a response to chronic stress, as these are clinically relevant responses to particularly emotional experiences.

When the researchers blocked the formation of R loops in front of the NPAS4 gene in the region of the brain known as the nucleus accumbens, they found that mice did not show a preference for cocaine. When a similar manipulation was performed in the prefrontal cortex, mice did not develop behaviors mimicking stress-induced anhedonia. These findings suggest that lnc-eRNAs, and associated R-loops, at the NPAS4 gene are an important process in the brain by which emotional experiences can produce behaviors associated with substance use or mood disorders.

“You need a change in the genetic basis of how everything is working, what is being transcribed, what is being formed in the cell to form stronger neural circuits that underlie behavior,” said Akiki.

The lnc-eRNA that the researchers focus on is highly conserved among species, which demonstrates the evolutionary relevance of this regulatory molecule. In fact, R-loops have been found in other cell types as well. The formation of R-loops with eRNAs is known to be an important mechanism in the immune system for developing immunity.

Akiki speculated that R-loops might be involved in the ability of neural circuits to adapt to experience-induced changes, drawing on her knowledge of immunology.

“I didn't think that evolution would favor a different mechanism for neurons,” she said. “We found that neurons, like immune cells, can respond to a stimulus through the formation of an R-loop.”

In the future, the research team wants to understand how ubiquitous this genetic regulatory mechanism is in the brain.

“If this really is a general mechanism, we want to see how stable it is and how it gets disrupted in pathological conditions,” said Taniguchi.

This newly discovered genetic mechanism could contribute to the way we respond to emotionally significant experiences in life. Ultimately, this finding helps to deepen our understanding of how the brain interprets experiences to influence adaptive behavior.

“This is a new way of thinking about how genes can be turned on” tells Cowan.

By developing a deeper understanding of the fundamental genetic processes that lead to behavioral changes, the findings of this paper may potentially inform novel applications of RNA-based therapies for the treatment of psychiatric disorders.

# # #

Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under T32DA007288, R01DA032708 and P50DA046373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
 

About MUSC
Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $358.9 million in research funds in fiscal year 2024, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding. For information on academic programs, visit musc.edu.

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned or governing interest), with approximately 2,700 beds and five additional hospital locations in development, more than 350 telehealth sites and nearly 750 care locations situated in all regions of South Carolina. In 2024, for the 10^th consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC has a total enterprise annual operating budget of approximately $7.1 billion. The 31,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, contract employees, affiliates and care team members who deliver groundbreaking education, research and patient care.

About the SCTR Institute
The South Carolina Clinical & Translational Research (SCTR) Institute is the catalyst for changing the culture of biomedical research, facilitating the sharing of resources and expertise and streamlining research-related processes to bring about large-scale change in the clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice. To learn more, visit https://research.musc.edu/resources/sctr